The Effect Of Stimulation Of Two Different Dendritic Cells On Hepatocellular Carcinoma Cytotoxic T Lymphocyte In Vitro

To date, human tumor immunotherapy has met with only limited success. Among the reasons for this have been the limited availability of tumor-associated antigens and the inability to deliver such antigens in a manner that renders them immunogenic in patients with cancer, the role of dendritic cells (DC) as the pivotal antigen-presenting cells (APC) that initiate immune responses may provide the basis for generating more effective anti-tumor immune responses, generation of an effective immune response requires that antigens be processed and presented to T lymphocytes by antigen-presenting cells, the most efficient of which are DCs, many reports of tumor regression following delivery of autologous tumor antigen-pulsed DCs suggest that defective antigen presentation may play a key role in tumor escape. The use of density-based isolation is, however, limited by the low frequency of DC precursors in blood, representing around 1% of peripheral blood mononuclear cells (PBMC). As a result, a leukapheresis must be performed to generate sufficient numbers of DCs for therapeutic vaccination in humans. To observe T lymphocyte in vitro stimulated by diverse DCs pulsed with mage-1 nine peptide induce different anti-hepatocellular carcinoma cell immune response in our experiment.Isolated and purified two kind of DCs from peripheral blood by combination of granulocyte /macrophage colony stimulating factor,interleukin...